BMC psychiatry · 2025
Evaluating the efficacy of radically open dialectical behavior therapy (RO-DBT) in patients with anorexia nervosa: study protocol for a randomized controlled clinical trial.
СтатьяПротокол клинического исследованияНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Avila-Parcet Aina, Martín-Blanco Ana, Gawron Leonor, Cano Marta, Peña-Arteaga Víctor De la, Carceller-Sindreu Mar, Soler Joaquim, Portella Maria J, Faustino Gloria, Cardoner Narcís, Carmona I Farrés Cristina
Аннотация
BACKGROUND: Anorexia nervosa (AN) is a severe and disabling disorder, with relapse rates as high as 50% after the first episode, posing a significant challenge for clinicians. Most therapies excessively focus on nourishment, resulting in temporary weight restoration but with no improvements in general well-being and quality of life. Radically Open Dialectical Behavior Therapy (RO-DBT) is a transdiagnostic treatment designed to address overcontrol, a key aspect in the functioning of patients with AN. To date, no clinical trial (CT) has shown its efficacy in these patients or evaluated its neurobiological mechanism of action.
METHODS: A randomized CT in weight restored adult AN patients will be conducted, with one group receiving treatment as usual (TAU) and the other TAU plus RO-DBT, with the main outcome being quality of life. Secondary variables will include eating disorders (EDs) symptoms, overcontrol characteristics, autistic traits, and neuroimaging changes.
DISCUSSION: The results will address a gap in knowledge regarding AN treatment, with the expectation that patients receiving TAU with RO-DBT will exhibit improved quality of life and experience fewer relapses at the one-year follow-up. This is the first study examining neuroimaging changes in RO-DBT to better understand its underlying mechanisms.
TRIAL REGISTRATION: The study has been registered in ClinicalTrials.gov in September 22, 2023. It can be found in https://classic.
CLINICALTRIALS: gov/ct2/show/NCT06050421 .
TRIAL REGISTRATION NUMBER: NCT06050421.
METHODS: A randomized CT in weight restored adult AN patients will be conducted, with one group receiving treatment as usual (TAU) and the other TAU plus RO-DBT, with the main outcome being quality of life. Secondary variables will include eating disorders (EDs) symptoms, overcontrol characteristics, autistic traits, and neuroimaging changes.
DISCUSSION: The results will address a gap in knowledge regarding AN treatment, with the expectation that patients receiving TAU with RO-DBT will exhibit improved quality of life and experience fewer relapses at the one-year follow-up. This is the first study examining neuroimaging changes in RO-DBT to better understand its underlying mechanisms.
TRIAL REGISTRATION: The study has been registered in ClinicalTrials.gov in September 22, 2023. It can be found in https://classic.
CLINICALTRIALS: gov/ct2/show/NCT06050421 .
TRIAL REGISTRATION NUMBER: NCT06050421.